Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 4Stomach Neoplasms 2Melanoma 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Malignant Solid Tumour 1Liver Neoplasms 1Fibrosis 1Colorectal Neoplasms 1Colorectal Cancer Metastatic 1Carcinoma 1

Interventions

Blood Specimen Collection 6Magnetic Resonance Spectroscopy 4Tenofovir 3Liver Transplantation 3Specimen Handling 2Sorafenib 2Simvastatin 2tremelimumab 1sonidegib 1sofosbuvir-velpatasvir drug combination 1peginterferon alfa-2a 1navitoclax 1maltodextrin 1hepatitis B hyperimmune globulin 1durvalumab 1contrast agent BR1 1bavituximab 1atezolizumab 1apixaban 1adefovir dipivoxil 1Viusid 1Vitamin D 1User-Centered Design 1Surveys and Questionnaires 1Sunitinib 1Spermine Synthase 1Sonazoid 1Sampling Studies 1Radiotherapy 1Radiofrequency Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fibrosis × ARQ 197 × Gastrointestinal × Clear all
NCT00802555 2012-07-12

Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

Phase 1 Completed
21 enrolled
Gastrointestinal

Fibrosis, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡